Malcolm J. Moore
University Health Network · 549 works · 74,112 citations · h-index 102
Top works
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
- K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
- Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
- Cetuximab for the Treatment of Colorectal Cancer
- Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
- The repertoire of mutational signatures in human cancer
- A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- Pan-cancer analysis of whole genomes
- Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.
- Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.
- Advanced pancreatic carcinoma: current treatment and future challenges
- Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain
- Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer